|
Age in years, mean (SE)
|
50.0 (13.0)
|
56.0 (11.8)
|
48.1 (12.4)
|
57.3 (8.7)
|
|
Sex (female), %
|
82.7
|
85.0
|
75.5
|
72.0
|
|
Disease duration in months, mean (SE)
|
12.9 (7.1)
|
114.0 (119.2)
|
-
|
-
|
|
Body mass index, mean (SE)
|
31.4 (7.8)
|
-
|
31.7 (7.6)
|
-
|
|
Global European admixture estimate, mean (SE)
|
0.17 (0.09)
|
0.16 (0.10)
|
0.16 (0.09)
|
0.17 (0.10)
|
|
Number of tender joints, median (IQR 25–75)
|
4.0 (1.0–12.0)
|
4.0 (1.0–9.5)
|
-
|
-
|
|
Number of swollen joints, median (IQR 25–75)
|
3.0 (1.0–7.0)
|
4.0 (1.0–10.0)
|
-
|
-
|
|
Medications
| | | | |
|
Biologics ever used (%)
|
4.4
|
-
|
19.5
|
-
|
|
Other DMARDs (%)
|
81.4
|
-
|
87.1
|
-
|
|
Methotrexate, current use (%)
|
63.9
|
60.3
|
-
|
-
|
|
Radiographic score, mean (SE)
| | | | |
|
Joint-erosion score
|
1.6 (4.3)
|
10.7 (18.5)
| | |
|
Joint-narrowing score
|
2.1 (5.7)
|
18.1 (27.7)
| | |
|
Total score
|
3.7 (9.4)
|
28.8 (44.1)
| | |
